201 related articles for article (PubMed ID: 30776447)
21. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
23. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
[TBL] [Abstract][Full Text] [Related]
24. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM; Dedes KJ; Matter-Walstra K; Schwenkglenks M; Gautschi O; Siano M; Aebersold DM; Plasswilm L; Lupatsch JE;
Radiother Oncol; 2018 Nov; 129(2):257-263. PubMed ID: 30104008
[TBL] [Abstract][Full Text] [Related]
25. Complaint-Directed Mini-Interventions for Depressive Symptoms: A Health Economic Evaluation of Unguided Web-Based Self-Help Interventions Based on a Randomized Controlled Trial.
Wijnen BF; Lokman S; Leone S; Evers SM; Smit F
J Med Internet Res; 2018 Oct; 20(10):e10455. PubMed ID: 30274958
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of FENO-based and web-based monitoring in paediatric asthma management: a randomised controlled trial.
Beerthuizen T; Voorend-van Bergen S; van den Hout WB; Vaessen-Verberne AA; Brackel HJ; Landstra AM; van den Berg NJ; de Jongste JC; Merkus PJ; Pijnenburg MW; Sont JK
Thorax; 2016 Jul; 71(7):607-13. PubMed ID: 27048197
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
28. Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
Veronesi G; Navone N; Novellis P; Dieci E; Toschi L; Velutti L; Solinas M; Vanni E; Alloisio M; Ghislandi S
Lung Cancer; 2020 May; 143():73-79. PubMed ID: 32234647
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
Roussel R; Martinez L; Vandebrouck T; Douik H; Emiel P; Guery M; Hunt B; Valentine WJ
J Med Econ; 2016; 19(2):121-34. PubMed ID: 26413789
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
Schremser K; Rogowski WH; Adler-Reichel S; Tufman AL; Huber RM; Stollenwerk B
Pharmacoeconomics; 2015 Nov; 33(11):1215-28. PubMed ID: 26081300
[TBL] [Abstract][Full Text] [Related]
32. A pragmatic multicentered randomized controlled trial of yoga for chronic low back pain: economic evaluation.
Chuang LH; Soares MO; Tilbrook H; Cox H; Hewitt CE; Aplin J; Semlyen A; Trewhela A; Watt I; Torgerson DJ
Spine (Phila Pa 1976); 2012 Aug; 37(18):1593-601. PubMed ID: 22433499
[TBL] [Abstract][Full Text] [Related]
33. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer.
Esnaola NF; Lazarides SN; Mentzer SJ; Kuntz KM
J Clin Oncol; 2002 Jan; 20(1):263-73. PubMed ID: 11773178
[TBL] [Abstract][Full Text] [Related]
34. A guided and unguided internet- and mobile-based intervention for chronic pain: health economic evaluation alongside a randomised controlled trial.
Paganini S; Lin J; Kählke F; Buntrock C; Leiding D; Ebert DD; Baumeister H
BMJ Open; 2019 Apr; 9(4):e023390. PubMed ID: 30967405
[TBL] [Abstract][Full Text] [Related]
35. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
37. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.
Bourbeau J; Granados D; Roze S; Durand-Zaleski I; Casan P; Köhler D; Tognella S; Viejo JL; Dal Negro RW; Kessler R
Int J Chron Obstruct Pulmon Dis; 2019; 14():645-657. PubMed ID: 30936689
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]